The chemistry of radioactive materials is known as radiochemistry. The presence of trace amounts of radioactive reagents distinguishes radiochemistry from conventional chemistry. The quantities of radioactive molecules in the combination are frequently lower than the contaminants introduced by solvent and other reagents. One of the primary tools for biomedical science is the radio isotopically labelled parent drug or its metabolite, which operates like and can trace its non-radioactive counterpart. Scientists have been able to analyze practically every element of a drug's behavior in vivo thanks to these radiolabeled molecules.
Hybrid imaging technology offers the ability to provide "one-stop" imaging with improved specificity, attenuation correction, and localization, allowing for more precise diagnosis. The fusing of two or more imaging methods into a single, new form of imaging is known as hybrid imaging. This new form is usually synergistic, meaning it is more potent than the sum of its parts.
Small amounts of radioactive materials called radiotracers are injected into the bloodstream, inhaled, or ingested in nuclear medicine imaging. Nuclear medicine imaging gives information that conventional imaging procedures cannot always provide, and it has the potential to detect disease at an early stage.
- Radiolabeled Drugs
- In Vivo Drug Metabolism
- Pharmacokinetic Studies
- Molecular Imaging
- Hybrid Imaging in Diagnosis
- Radiopharmaceuticals
- Radioactive Tracers
A C Matin
Stanford University, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Luis Jesus Villarreal Gomez
Autonomous University of Baja California, Mexico
John K Maesaka
NYU Langone Hospital Long Island, United States
Richard Denk
SKAN AG, Switzerland
Peter B Chase
Essentia Health- St. Mary's Medical Center, United States
Saliha Koc Aslan
Acibadem Healthcare Group, Turkey
Ana Isabel Rocha Faustino
University of Evora, Portugal
Narapereddy Krishna Prasad
Reckitt Benckiser LLC, United States
Title : Extracellular vesicles as delivery vehicles of therapeutic compounds
Stefania Raimondo, University of Palermo, Italy
Title : EU GMP annex1 barrier system and PIC/s annex 2A on cell and gene therapy
Richard Denk, SKAN AG, Switzerland
Title : Role of nanoformulations in treating Cystic Fibrosis
Bhupendra Gopalbhai Prajapati, Ganpat University, India
Title : Dual GIP/GLP-1 receptor stimulation in treatment of type 2 diabetes mellitus – The ground-breaking 'twincretin' approach
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Pathology and patient safety: The vital role of electronic medical record and pathology informatics in error reduction and precision medicine
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : mRNA-based systemically delivered directed gene therapy using nanomaterials
A C Matin, Stanford University, United States
Title : Colon-specific scallop hydrolysates/Κ-carrageenan hydrogel loaded with curcumin alleviates dss-induced colitis through modulation of inflammatory cytokines and gut microbiota
Hai Tao Wu, Dalian Polytechnic University, China
Title : Mucoadhesive electrospun fibrous systems for the fast and sustained delivery of drugs
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : General and local anaesthetic agents: An analysis of their safety data
Francesca Gargano, Campus Bio-Medico University of Rome, Italy
Title : 15,16-dihydrotanshinone-I-laden PLGA-co-PEG nanoparticles are potential therapeutic agents for the treatment of colorectal cancer by targeting the β-catenin/CD36 axis
Kwan Hiu Yee, Hong Kong Baptist University, China